A rare clinical presentation of COVID 19 : opsoclonus-myoclonus ataxia syndrome
Copyright (c) 2024 Adalet Altunsoy, Nizamettin Kemirtlek, Halime Araz, Ebru Bilge Dirik, Esragül Akıncı..
INTRODUCTION: Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal.
CASE PRESENTATION: We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey.
DISCUSSION: OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of infection in developing countries - 18(2024), 2 vom: 29. Feb., Seite 188-194 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Altunsoy, Adalet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 27.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3855/jidc.17927 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369740386 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369740386 | ||
| 003 | DE-627 | ||
| 005 | 20240328000159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3855/jidc.17927 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM369740386 | ||
| 035 | |a (NLM)38484346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Altunsoy, Adalet |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A rare clinical presentation of COVID 19 |b opsoclonus-myoclonus ataxia syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright (c) 2024 Adalet Altunsoy, Nizamettin Kemirtlek, Halime Araz, Ebru Bilge Dirik, Esragül Akıncı. | ||
| 520 | |a INTRODUCTION: Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal | ||
| 520 | |a CASE PRESENTATION: We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey | ||
| 520 | |a DISCUSSION: OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IVIG | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a intravenous immunoglobulin | |
| 650 | 4 | |a opsoclonus-myoclonus ataxia syndrome | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Kemirtlek, Nizamettin |e verfasserin |4 aut | |
| 700 | 1 | |a Araz, Halime |e verfasserin |4 aut | |
| 700 | 1 | |a Dirik, Ebru Bilge |e verfasserin |4 aut | |
| 700 | 1 | |a Akıncı, Esragül |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection in developing countries |d 2007 |g 18(2024), 2 vom: 29. Feb., Seite 188-194 |w (DE-627)NLM191178497 |x 1972-2680 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:2 |g day:29 |g month:02 |g pages:188-194 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3855/jidc.17927 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 2 |b 29 |c 02 |h 188-194 | ||